ALK and cancer: ALINA (NCT03456076) was a global, randomized, open-label, phase III trial evaluating the clinical benefit of adjuvant alectinib compared to standard chemotherapy in patients with ALK-positive NSCLC in stage IB (tumors ≥ 4 cm), II, or IIIA (according to the 7th edition of the Cancer Staging Manual of the American Joint Committee on Cancer and the Union for International Cancer Control).